Trice Medical was founded to fundamentally improve orthopedic diagnostics.

Chris Yamamoto serves as Senior Vice President of Business Development and Strategy and is responsible for identifying, evaluating and executing inorganic growth opportunities across Bioventus. Chris has nearly 20 years of experience in mergers & acquisitions and business development having completed numerous transactions amounting to over $50 billion in value.

Prior to joining Bioventus, Chris was Vice President and Managing Director of Corporate Development at Becton Dickinson and Company. During his six years at Becton Dickinson, Chris played an instrumental role in transforming the company through two large-scale acquisitions (C.R. Bard and CareFusion), executing nearly 30 tuck-in acquisitions and equity investments and divesting a number of non-core businesses. Prior to Becton Dickinson, Chris was a Vice President at The Blackstone Group. Chris also worked at Fox Paine, Thoma Cressey, UBS Investment Bank and other institutions.

Chris received a Bachelor of Arts in Economics cum laude from Williams College.

Mike has over 10 years of experience in both design and manufacturing of medical devices, specializing in ultrasonic systems.

Prior to joining Trice Medical and Tenex Health, he managed manufacturing and service of phacoemulsification equipment and accessories at American Optisurgical, Inc. With Tenex Health, he assumed a lead role in the planning, development and implementation of the processes required for the product realization of the Tenex Health TX^® System. Mike received his Bachelor’s degree from the University of California, Los Angeles.

Ryan brings with him over twenty years of healthcare experience, of which the last nineteen years were with Boston Scientific. He received his Bachelor of Arts from SUNY, New Paltz and his Master of Science from New School University.

He will be responsible for developing and executing the Global Marketing strategy including, Health Economics and Reimbursement, Clinical Strategy and Product Development across Trice Medical’s growing, innovative business.

Over the course of his career, Ryan advanced through multiple leadership roles within Sales, Marketing and Market Development. In his most recent position as Vice President for Single-Use Scopes and Global Markets, he was instrumental in positioning Boston Scientific as a global leader in the Gastrointestinal Single Use Endoscopy space, where he led a team that would be the first to launch several disruptive disposable endoscopes.

Mr. Intintoli joined Trice Medical in March of 2015 as Vice President of Engineering. He brings thirty-five years of professional experience in optical and medical device development. His unique combination of engineering, operations, regulatory and clinical skills has formed Trice’s current world-class development team and product supply chain.

Mr. Intintoli spent the prior thirteen years leading a team at PhotoMedex developing and building their surgical product offerings. Prior to PhotoMedex, he held ever-increasing engineering and operational roles with Surgical Laser Technologies, Quantronix Corporation, Kearfott Division of the Singer Company and the Laboratory of Laser Energetics.

Mr. Intintoli has a B.S. degree in optical engineering (with distinction) from the University of Rochester Institute of Optics. He is a fellow of the American Society for Laser Medicine and Surgery and a member of other optical societies.

Michael Schrauben is the Director of Asset Allocation for MERS. He brings valuable global macroeconomic insight to the group, which facilitates strategic decision making and portfolio asset allocation. Michael co-manages the Fund’s internal equity program and also oversees the Fund’s Diversifying Strategies portfolio, which targets uncorrelated alternative investment strategies to reduce portfolio beta and drawdown. He manages the Asset Allocation Team, which monitors the Fund’s asset allocation and risk and provides allocation recommendations to the Portfolio Review Committee. He is a voting member on the Portfolio Review Committee, which is responsible for all portfolio management decisions including external asset manager selection and monitoring. Michael joined MERS in 2008.

Education

• BA with High Honors, Finance – Michigan State University, Eli Broad College of Business
• Michigan State University Financial Markets Institute
• Michigan State University Honors College

Professional Designation

• Chartered Financial Analyst (CFA) Charterholder

Sarah has twelve years of International Sales and Marketing experience in Healthcare. Her background is a strong mix of developing customer relationships, launching products, strategic planning and industry knowledge.

She spent nine years in Sports Medicine Orthopedics working in Sales and Marketing at Smith and Nephew, and more recently starting her own business focusing on bringing innovative sports medicine technologies into Europe. Sarah moved from the UK to Malvern, PA in 2018 to join the leadership team at Trice Medical.

Sarah holds a Psychology BSc from University of Surrey, UK.

Vasant brings extensive experience in R&D and technology. Prior to Smith & Nephew, Vasant was Senior Vice President of Technical Operations at Thoratec Corporation, a leader in mechanical circulatory support solutions for the treatment of heart failure. In this role, he provided leadership to a 600 member team, with responsibility for global R&D, Program Management, Operations and Quality. Prior to Thoratec, Vasant had an 18-year career at Medtronic, starting as a Staff Scientist and, progressing through more senior roles, ultimately becoming Vice President of Product Development for the Implantable Defibrillator Business. Vasant holds a Ph.D degree in Biomedical Engineering from Rutgers University, USA and an MBA degree from the Carlson School of Management, Minnesota.

Randy joined Garheng in starting HealthQuest in 2013. After a successful career as a MedTech entrepreneur, Randy switched careers because he also saw the opportunities overlooked by investors and felt that he could help innovative young businesses by applying the lessons he had learned by leading those kinds of companies. He is currently on the board of HealthQuest portfolio companies Vestagen, Virmedica, Avizia, Springbuk and Magnolia Medical and is a Board Observer at Trice Medical.

Randy’s industry successes include starting NovaMin Technology, Inc. leading it through financing, growth and eventual acquisition by GlaxoSmithKline (at a 10x return on capital), a turn-around of USBiomaterials Corp’s bone-grafting business from perennial money-loser to a profitable spin-out (now NovaBone Products) and being a member of the early management team at LensCrafters as it emerged from start-up to market leader. These businesses each solved real problems for patients and users and represent the kind of opportunities that Randy seeks as he thinks about opportunities at HealthQuest.

Randy is committed to supporting entrepreneurs both in HealthQuest’s portfolio and beyond, including as past chair of the Gainesville Area Innovation Network, and  advisory board member for the Florida Institute for the Commercialization of Public Research.

Randy graduated from Georgia Tech with a BS in Management Science. He spent the first half of his career in consumer products marketing, starting in brand management at Procter & Gamble. Randy lives in Gainesville, Florida with his wife when he’s not living out of a tent as he hikes and explores the backcountry.

Alan Davis, MD, is a highly regarded orthopaedic surgeon at the Cleveland Clinic, as well as a team physician for the United States Olympic Team. He was an Academic All-American and Captain of one of Michigan State’s most successful football teams. He has been involved in multiple medical and metabolic technologies including those related to sports drinks and the metabolic needs of high performance athletes, as well as computerized software design for maximized bio mechanical muscle training. Dr. Davis is also a member of the Orthopaedic and Rheumatologic Peer Review Committee, which is part of the Cleveland Clinic Innovation. The committee evaluates any new ideas for new devices or products.

Eric Salzman is the Chief Executive Officer of publicly traded Safeguard Scientifics, which provides capital and relevant expertise to fuel the growth of technology-driven businesses in healthcare, financial services, and digital media. Eric was appointed CEO in October 2020 and currently represents Safeguard on the boards of Aktana, Infobionic, meQuilibrium, Prognos, Syapse, Trice Medical, and Clutch.

For more than 25 years, Eric has helped technology focused companies drive growth and navigate major periods of transformation, leading the implementation of strategic operating plans, corporate finance transactions and M&A. He has served as executive chairman, non-executive chairman, special committee chair and independent director at more than 25 public and private companies including portfolio companies of Ares, Athyrium, Blackstone, Carlyle, Francisco Partners and KKR. Presently, Eric also serves as an independent director, Chairman of the Compensation Committee, and member of the Audit Committee at publicly traded 8×8, Inc.

Earlier in his career, Eric spent nearly ten years employed by Lehman Brothers as a Managing Director in the Private Equity and Principal Investing Group as well as a Managing Director in the Global Trading Strategies Division.  Eric earned a B.A. Honors from the University of Michigan and an MBA from Harvard University.

Mark is an experienced professional with twenty years of progressively increasing responsibility in the medical device industry. Mark brought a unique combination of sales, marketing, operational and strategic planning skills to Trice Medical. Since Joining Trice in 2016, the organization has evolved into a technology company that has a broad portfolio of products for minimally invasive diagnostic and therapeutic orthopedic procedures.

Prior to joining Trice, he spent eight years helping to build Smith & Nephew’s U.S. Sports Medicine Division to the powerhouse that it is today. In his last role there, he was responsible for all U.S. Commercial Operations (roughly $600M.) Mark also worked on M&A activities and served as the U.S. Commercial Integration Lead for Smith and Nephew’s largest acquisition, Arthrocare.

Prior to Smith & Nephew, Mark spent eight years with Boston Scientific in roles of increasing responsibility within the Gastroenterology and Neurovascular Divisions.
Mark is a graduate of the University of Richmond where he earned his B.A.